Pragmatic consideration of recent randomized, placebo-controlled clinical trials for treatment of fibromyalgia.
A flurry of recent randomized, placebo-controlled trials assessing dissimilar pharmacotherapeutic treatment options for fibromyalgia (FM) have been presented in the past few years. This review evaluates these trials in light of recent pathophysiological concepts germane to FM, including mood disorders, autonomic dysregulation, altered sleep stage architecture, and the diagnostic tender point controversy. Studies with gabapentin, pregabalin, duloxetine, milnacipran, sodium oxybate, and pramipexole for treatment of FM are discussed.
Holman
Andrew J
AJ
Pacific Rheumatology Research, Renton, WA 98055, USA. AJHSeattle@aol.com
D005356:Fibromyalgia / Q000150:complications / Q000188:drug therapy* / Q000503:physiopathology; D006801:Humans; D019964:Mood Disorders / Q000150:complications / Q000188:drug therapy / Q000503:physiopathology; D014179:Neurotransmitter Uptake Inhibitors / Q000627:therapeutic use; D010919:Placebos; D016032:Randomized Controlled Trials as Topic / Q000379:methods / Q000639:trends*; D012893:Sleep Wake Disorders / Q000150:complications / Q000188:drug therapy / Q000503:physiopathology; D016896:Treatment Outcome
D014179:Neurotransmitter Uptake Inhibitors; D010919:Placebos